ES2191702T3 - Fv monocatenarios anti-egfr y anticuerpos anti-egfr. - Google Patents

Fv monocatenarios anti-egfr y anticuerpos anti-egfr.

Info

Publication number
ES2191702T3
ES2191702T3 ES95913134T ES95913134T ES2191702T3 ES 2191702 T3 ES2191702 T3 ES 2191702T3 ES 95913134 T ES95913134 T ES 95913134T ES 95913134 T ES95913134 T ES 95913134T ES 2191702 T3 ES2191702 T3 ES 2191702T3
Authority
ES
Spain
Prior art keywords
egfr
antibodies
antibody
books
fvs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95913134T
Other languages
English (en)
Inventor
A Cathrine Kettleborough
Mary M Bendig
Keith H Ansell
Detlef Gussow
Jaime Adan
Francesc Mitjans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2191702T3 publication Critical patent/ES2191702T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE A NUEVOS ANTICUERPOS ANTI-EGFR Y A CADENAS SIMPLES FVS (SCFVS) DE LOS MISMOS QUE PUEDEN OBTENERSE A PARTIR DE LIBRERIAS DE ANTICUERPOS CONSTRUIDAS A PARTIR DE CELULAS DE UN MAMIFERO INMUNIZADO, PREFERIBLEMENTE UN RATON. DOS DE LOS FVS DE CADENA SIMPLE AISLADOS A PARTIR DE LAS LIBRERIAS DE ANTICUERPOS FUERON MODIFICADOS GENETICAMENTE PARA CREAR MOLECULAS COMPLETAS DE ANTICUERPOS PARCIALMENTE HUMANIZADOS. ESTOS ANTICUERPOS QUIMERICOS ANTI-EGFR CONTIENE REGIONES CONSTANTES DE INMUNOGLOBULINAS HUMANAS Y PUEDEN UTILIZARSE ASI COMO LOS FVS DE CADENA SIMPLE COMO AGENTES PARA LA DIAGNOSIS Y LA TERAPIA DE TUMORES HUMANOS.
ES95913134T 1994-03-17 1995-03-16 Fv monocatenarios anti-egfr y anticuerpos anti-egfr. Expired - Lifetime ES2191702T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94104160 1994-03-17
EP94118970 1994-12-02

Publications (1)

Publication Number Publication Date
ES2191702T3 true ES2191702T3 (es) 2003-09-16

Family

ID=26135522

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95913134T Expired - Lifetime ES2191702T3 (es) 1994-03-17 1995-03-16 Fv monocatenarios anti-egfr y anticuerpos anti-egfr.

Country Status (20)

Country Link
US (1) US5844093A (es)
EP (1) EP0699237B1 (es)
JP (2) JPH08510922A (es)
KR (1) KR100376038B1 (es)
AT (1) ATE232902T1 (es)
AU (1) AU2071695A (es)
CA (1) CA2163012C (es)
CZ (1) CZ292061B6 (es)
DE (1) DE69529649T2 (es)
DK (1) DK0699237T3 (es)
ES (1) ES2191702T3 (es)
HU (1) HU221001B1 (es)
MX (1) MX9504802A (es)
NO (1) NO322252B1 (es)
PL (1) PL181342B1 (es)
PT (1) PT699237E (es)
RU (1) RU2170257C2 (es)
SK (1) SK283889B6 (es)
UA (1) UA41929C2 (es)
WO (1) WO1995025167A1 (es)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0659439B1 (en) 1993-12-24 2001-10-24 MERCK PATENT GmbH Immunoconjugates
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
AU4373197A (en) * 1996-09-19 1998-04-14 Diagnocure Inc. Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
EP1500329B1 (en) * 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
WO1999011792A1 (fr) * 1997-09-02 1999-03-11 Sumitomo Pharmaceuticals Company, Limited Anticorps a simple brin dirige contre une proteine noyau du virus de l'hepatite b, gene correspondant et agent therapeutique de l'hepatite b les contenant
DE19744531A1 (de) * 1997-10-09 1999-05-27 Klaus Dr Rer Nat Bosslet Bindemoleküle gegen Rezeptor-Ligand-Komplexe
DK1032660T3 (da) 1997-11-17 2010-01-18 Micromet Ag Fremgangsmåde til identivicering af bindingsstedsdominans som bevarer evnen til at binde til en epitop
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
BR9913435A (pt) 1998-08-28 2001-09-25 Genentech Inc Composições compreendendo anticorpos anti-fator ix/ixa humanos, ácido nucléico isolado, vetor, célula hospedeira, método de produção de anticorpo ou fragmento de anticorpo, artigo industrializado, método de tratamento de um mamìfero e composição farmacêutica
HK1047236A1 (zh) * 1999-05-14 2003-02-14 Imclone Llc 用表皮生长因子受体拮抗剂治疗难治的人肿瘤
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US7361338B2 (en) * 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US6790631B1 (en) * 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
CN1239701C (zh) * 2000-05-19 2006-02-01 梨树化学株式会社 抗表皮生长因子受体的人源化抗体
EP1314740A4 (en) * 2000-06-14 2005-01-19 Med & Biological Lab Co Ltd PREPARATION METHODS OF FLUORESCENCE PROTEIN FUSIONED SCFV ANTIBODIES
US7598055B2 (en) * 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US8697394B2 (en) 2000-06-28 2014-04-15 Glycofi, Inc. Production of modified glycoproteins having multiple antennary structures
EP2322644A1 (en) * 2000-06-28 2011-05-18 GlycoFi, Inc. Methods for producing modified glycoproteins
US7449308B2 (en) * 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
AU9500201A (en) * 2000-08-09 2002-02-18 Imclone Systems Inc Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
AU2001288342A1 (en) * 2000-08-21 2002-03-04 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2002241922B2 (en) * 2001-01-17 2007-10-25 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
GB0103389D0 (en) * 2001-02-12 2001-03-28 Novartis Ag Organic compounds
AU2002257067A1 (en) 2001-03-14 2002-09-24 Myriad Genetics, Inc Tsg101-gag interaction and use thereof
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
EP1392359B2 (en) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US20020193569A1 (en) * 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
NZ530212A (en) * 2001-06-13 2006-09-29 Genmab As An isolated human monoclonal antibody that binds to human epidermal growth factor receptor (EGFR)
AU2003222568B2 (en) 2002-01-11 2009-05-07 Bioasis Technologies, Inc. Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
ES2392525T3 (es) 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
WO2005044858A1 (en) 2003-11-07 2005-05-19 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
WO2004043405A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US20040147428A1 (en) * 2002-11-15 2004-07-29 Pluenneke John D. Methods of treatment using an inhibitor of epidermal growth factor receptor
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
EP2332990A1 (en) * 2004-03-19 2011-06-15 Imclone LLC Human anti-epidermal growth factor receptor antibody
AU2005236068C1 (en) * 2004-04-21 2012-08-30 Beth Israel Deaconess Medical Center, Inc. Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
KR20120064120A (ko) 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
HRP20140338T1 (hr) 2005-07-25 2014-06-20 Emergent Product Development Seattle, Llc Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
JP2009518024A (ja) * 2005-12-06 2009-05-07 ドマンティス リミテッド Ｅｇｆｒおよび／またはｖｅｇｆに対して結合特異性を有するリガンドおよびその使用法
US7503217B2 (en) * 2006-01-27 2009-03-17 Weatherford/Lamb, Inc. Sonar sand detection
EP1994144B1 (en) * 2006-03-06 2017-11-22 Agency for Science, Technology and Research Human embryonic stem cell methods and podxl expression
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
EP2975057A1 (en) 2006-07-10 2016-01-20 Fujita Health University Novel anti-cd73 antibody
KR101519672B1 (ko) * 2006-12-07 2015-05-29 노파르티스 아게 Ｅｐｈｂ３에 대한 길항제 항체
CN101605561A (zh) * 2006-12-22 2009-12-16 诺韦利克斯治疗有限公司 通过至少一种表皮生长因子受体特异性抗体或其衍生物的糖尿病治疗
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
ES2542152T3 (es) 2007-03-15 2015-07-31 Ludwig Institute For Cancer Research Ltd. Método de tratamiento que emplea anticuerpos de EGFR e inhibidores de Src y formulaciones relacionadas
WO2008154927A1 (en) * 2007-06-21 2008-12-24 Genmab A/S Novel methods for treating egfr-associated tumors
CN108424454B (zh) 2007-08-14 2022-05-31 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
ES2536772T3 (es) 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
EP2365003A1 (en) 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
BRPI0913366A8 (pt) 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
PE20100092A1 (es) 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
NZ603698A (en) 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
KR20110031393A (ko) 2008-07-21 2011-03-25 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
KR101108642B1 (ko) * 2009-09-29 2012-02-09 주식회사 녹십자 표피 성장 인자 수용체에 특이적으로 결합하는 항체
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20120282274A1 (en) * 2009-11-20 2012-11-08 Northshore University Health System Research Institute Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment
EP2507381A4 (en) 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
CN102167743B (zh) * 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗egfr单克隆抗体、其制备方法及用途
CN102946906B (zh) 2010-04-23 2015-07-15 弗·哈夫曼-拉罗切有限公司 生产异源多聚体蛋白质
EP2578682B1 (en) * 2010-06-04 2016-07-27 Toagosei Co., Ltd. Antibody and use thereof
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PE20140229A1 (es) 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
KR101273918B1 (ko) * 2010-09-17 2013-06-13 강원대학교산학협력단 인간 항-상피세포성 성장인자수용체 Ｆａｂ 항체 및 이를 포함하는 종양 치료용 약학 조성물
CN103298489A (zh) 2010-10-29 2013-09-11 伊缪诺金公司 新型egfr结合分子及其免疫偶联物
CN105399831A (zh) 2010-10-29 2016-03-16 伊缪诺金公司 非拮抗性egfr结合分子及其免疫偶联物
CN103649117B (zh) 2011-02-04 2016-09-14 霍夫曼-拉罗奇有限公司 Fc变体及其生成方法
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
JP6130307B2 (ja) 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム 再指向性免疫療法
ES2582869T3 (es) 2011-07-05 2016-09-15 Bioasis Technologies Inc Conjugados de P97-anticuerpo
CA2842492A1 (en) 2011-08-05 2013-02-14 Bioasis Technologies, Inc. P97 fragments with transfer activity
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
HK1200468A1 (en) 2011-09-30 2015-08-07 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
SG10201603411WA (en) 2011-10-28 2016-07-28 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
US9233171B2 (en) 2011-11-21 2016-01-12 Immunogen, Inc. Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugate
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
US9872904B2 (en) 2012-03-21 2018-01-23 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Photoimmunoconjugates for use in photodynamic therapy
WO2013173255A2 (en) * 2012-05-17 2013-11-21 Sorrento Therapeutics Inc. Antigen binding proteins that bind egfr
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
ES2647082T3 (es) 2012-07-31 2017-12-19 Bioasis Technologies Inc Proteínas desfosforiladas de la enfermedad de depósito lisosómico y métodos de uso de las mismas
KR20180008921A (ko) 2012-11-01 2018-01-24 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
JP6586412B2 (ja) 2013-03-13 2019-10-02 バイオアシス テクノロジーズ インコーポレイテッド ｐ９７のフラグメントおよびその使用
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
ES2774976T3 (es) 2013-04-29 2020-07-23 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
JP6603227B2 (ja) 2014-02-03 2019-11-06 バイオアシス テクノロジーズ インコーポレイテッド Ｐ９７融合タンパク質
DK3107562T3 (da) 2014-02-19 2019-12-16 Bioasis Technologies Inc P97-ids-fusionsproteiner
US10058619B2 (en) 2014-05-01 2018-08-28 Bioasis Technologies, Inc. P97-polynucleotide conjugates
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
CA2943707A1 (en) 2014-05-06 2015-11-12 Genentech, Inc. Production of heteromultimeric proteins using mammalian cells
JP5924795B2 (ja) 2014-06-13 2016-05-25 テンボロン オイ 複合体
CA2965414C (en) 2014-10-29 2024-01-09 Teva Pharmaceuticals Australia Pty Ltd Interferon .alpha.2.beta. variants
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
EA201792573A1 (ru) 2015-05-21 2018-04-30 Харпун Терапьютикс, Инк. Триспецифические связанные белки и способы их применения
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3352760B1 (en) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Cd3 binding polypeptides
JP7101621B2 (ja) 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． 単一ドメイン血清アルブミン結合タンパク質
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
JP7241677B2 (ja) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法
WO2018152033A1 (en) * 2017-02-14 2018-08-23 Promab Biotechnologies, Inc. Cd47-car-t cells
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
HRP20241268T1 (hr) 2017-10-13 2024-12-06 Harpoon Therapeutics, Inc. Trispecifični proteini i postupci primjene
CN109879964B (zh) * 2017-12-06 2022-08-05 北京科立思维生物科技有限公司 抗egfr单链抗体、抗pd1单链抗体及融合蛋白
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
KR20210020903A (ko) 2018-05-14 2021-02-24 하푼 테라퓨틱스, 인크. 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티
WO2020036852A1 (en) 2018-08-13 2020-02-20 Beijing Percans Oncology Co. Ltd. Biomarkers for cancer therapy
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
SG11202103022WA (en) 2018-09-25 2021-04-29 Harpoon Therapeutics Inc Dll3 binding proteins and methods of use
AU2019370276A1 (en) 2018-10-30 2021-06-10 Board Of Regents, The University Of Texas System Anti-CD79b antibodies and chimeric antigen receptors and methods of use thereof
CA3120800A1 (en) 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
WO2020163512A1 (en) 2019-02-05 2020-08-13 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis
US12516128B2 (en) 2019-05-14 2026-01-06 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
US20230183371A1 (en) * 2020-04-30 2023-06-15 Board Of Regents, The University Of Texas System Anti-cd79b antibodies and chimeric antigen receptors and methods of use thereof
EP3954393A1 (en) 2020-08-13 2022-02-16 Bioasis Technologies Inc. Combination therapies for delivery across the blood brain barrier
JP2023545099A (ja) 2020-10-08 2023-10-26 アフィメド ゲーエムベーハー 三重特異性バインダー
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
AU2022382368A1 (en) 2021-11-03 2024-05-02 Affimed Gmbh Bispecific cd16a binders
WO2025257588A1 (en) 2024-06-10 2025-12-18 Affimed Gmbh Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance
CN119101160B (zh) * 2024-10-25 2025-02-11 江苏百英生物科技有限公司 一种抗cd28纳米抗体、基于天然库筛选cd28纳米抗体的方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2016842A1 (en) * 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US5395750A (en) * 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
IT1271461B (it) * 1993-12-01 1997-05-28 Menarini Ricerche Sud Spa Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
GB9401182D0 (en) * 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect

Also Published As

Publication number Publication date
CZ301495A3 (en) 1996-02-14
EP0699237B1 (en) 2003-02-19
WO1995025167A1 (en) 1995-09-21
JPH08510922A (ja) 1996-11-19
PL311661A1 (en) 1996-03-04
AU2071695A (en) 1995-10-03
CA2163012C (en) 2009-12-08
DK0699237T3 (da) 2003-05-26
CA2163012A1 (en) 1995-09-21
NO322252B1 (no) 2006-09-04
PT699237E (pt) 2003-07-31
HUT73461A (en) 1996-08-28
HU9503285D0 (en) 1996-02-28
DE69529649T2 (de) 2003-12-18
ATE232902T1 (de) 2003-03-15
PL181342B1 (pl) 2001-07-31
NO954626D0 (no) 1995-11-16
NO954626L (no) 1995-11-16
JP2006025794A (ja) 2006-02-02
US5844093A (en) 1998-12-01
UA41929C2 (uk) 2001-10-15
CZ292061B6 (cs) 2003-07-16
SK283889B6 (sk) 2004-04-06
KR100376038B1 (ko) 2003-06-09
HU221001B1 (hu) 2002-07-29
MX9504802A (es) 1997-05-31
EP0699237A1 (en) 1996-03-06
RU2170257C2 (ru) 2001-07-10
SK143095A3 (en) 1996-11-06
DE69529649D1 (de) 2003-03-27

Similar Documents

Publication Publication Date Title
ES2191702T3 (es) Fv monocatenarios anti-egfr y anticuerpos anti-egfr.
PE20050376A1 (es) Anticuerpos dirigidos a m-csf
ATE171472T1 (de) Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
DE3751908D1 (de) Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
ES2231826T3 (es) Anticuerpos monoclonales anti-cd6 para el tratamiento y el diagnostico de la psoriasis.
DE69233191D1 (de) Cyclin d1 und seine cdna
BR0312692A (pt) anticorpos selecionados e peptìdeos de duramicina que se ligam a fosfolipìdios aniÈnicos e aminofosfolipìdios e seus usos no tratamento de infecções virais e cáncer
NO20045645L (no) Noytraliserende humant anti-IGFR-antistoff
DE69129743D1 (de) Humanisierte chimäre anti-"icam-1" antikörper, herstellungsverfahren und verwendung
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
BR0309254A (pt) Uso de um anticorpo anti-ctla-4
NO20076673L (no) Antistoffer rettet mot CD20 og anvendelser derav
ATE196607T1 (de) Verfahren zur ex vivo-immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer antikörper
UY27537A1 (es) "anticuerpos para cd40"
BRPI0417077A (pt) anticorpos de anti-mpl
EP0675904A4 (en) HUMANE NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST THE VIRUS FROM HUMAN THAT MAKES THE IMMUNE.
DE3784720D1 (de) Produkt, praeparat und methode zum bekaempfen der allergien.
ES2052077T3 (es) Un sistema de expresion para la produccion de anticuerpos monoclonales quimericos.
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
BRPI0414513A (pt) kid3 e anticorpos de kid3 que se ligam a ele
ES2173910T3 (es) Anticuerpos humanizados dirigidos contra el antigeno a33.
ATE11547T1 (de) Neue d-homosteroide, ihre verwendung und herstellung, sowie pharmazeutische praeparate damit.
NO965395D0 (no) Humane, monoklonale antistoffer som er spesifikke mot cellecyklus-uavhengig gliom-overflateantigen
ATE248189T1 (de) Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung